Evidence-based practice Healthcare delivery HRQOL Symptom management TRSC Background: Cancer treatment efficacy has improved with therapies at high or sustained dosages. However, there is increasing concern about symptom management and patients' quality of life. Objective: The objective of this study was to assess whether use of a Therapy-Related Symptom Checklist (TRSC) with oncology outpatients increases the number of symptoms documented and managed and whether this improves patients' health-related quality of life (HRQOL). Methods: This was a sequential cohort trial. Fifty-five oncology outpatients in treatment received standard of care (group 1, G1). Afterward, another 58 patients (group 2, G2) received standard of care at the same clinic; however, these patients additionally answered the TRSC immediately prior to each consultation. The TRSC results were then shared with clinicians. Repeated measures (2Y11 visits) were obtained of the number of patient treatment symptoms documented (medical records G1 and TRSC G2), HRQOL, and Karnofsky scores, n = 696 observations (328 G1 and 368 G2).
7.2% higher population averaged covariate-adjusted HRQOL than G1 patients (3.3 more points on HRQOL, P = .012). One hundred sixteen percent more covariate-and nonYcovariate-adjusted symptoms were documented/managed in G2 than G1 (6.14 symptoms vs 2.84, P G .0001). The HRQOL, TRSC, and Karnofsky scores correlated r 9 0.40. Conclusion: Use of patient-reported TRSC improves symptom documentation/management and patient HRQOL.
Implications for Practice: Study findings were consistent with recent research that has shown that use of checklists can have powerful influences on both quality and safety of healthcare services and patient outcomes.
A s the efficacy of cancer treatment has improved, more types of cancers are being treated with chemotherapy and radiotherapy at high or sustained dosages. Consequently, there is increased concern about symptom documentation and management and patients' quality of life. 1Y10 Underdocumentation of symptoms during clinic visits had been reported. 9 Symptom Monitoring, Symptom Management, and Self-care
Considerable information is available about the management of cancer treatmentYrelated symptoms, but often assessment scales measure only a single or small set of symptoms. Symptoms studied have included nausea and vomiting 11 ; taste change, loss of appetite, and weight loss 12 ; sore mouth/mucositis 13 ; fatigue, pain, and depression 14, 15 ; dyspnea 16 ; and paresthesias. 17 A recent review concluded that pain is well studied, but other symptoms need better understanding and assessment. 18 Although several multiple symptom scales have been developed 1, 4, 5, 19, 20 and described in reviews, 3 considerably less studies have assessed multiple symptoms while healthcare is actually being delivered. 21, 22 Multidisciplinary initiatives are underway to improve collection of patient-reported outcomes within clinical settings. 23Y25 Clinicians must rely on accurate patient-reported symptoms to manage treatment-related toxicities. Complexity of regimens makes it more likely that patients will experience potentially toxic or disturbing adverse effects, requiring prompt and effective self-care. Some cancer patients are successfully using self-care to complement medical and nursing care for symptom control. 6Y8,10,26Y29 Patients who participate in symptom monitoring are more satisfied and interact with providers more regarding symptom management. 28, 29 Effective self-care is increasingly regarded as a requisite of symptom management and adherence to treatment. Approaches to symptom management and the delivery of interventions consistent with and supportive of self-care include home care by trained nurses 10 and clinic-based interventions designed to manage specific symptoms, such as fatigue. 26 
Health-Related Quality of Life
Health-related quality of life (HRQOL) refers to a multidimensional construct that has physical, mental, social, economic, and spiritual domains. 30Y36 Several HRQOL scales specific to cancer have been developed including the HRQOL Linear Analogue Self-assessment (LASA) used in this study. 37, 38 The HRQOL-LASA has been found to be robustly related to symptom occurrence, severity, and patient functional status and easy to use in clinics. 37, 38 Health-related quality of life has been used as an outcome in chemotherapy, radiation and surgery, breast cancer, neuro-oncology, lung cancer, advanced cancer, and teleoncology. 1,33Y38
Design of Studies
Increasing calls for translational research and study designs that better reflect real-world treatment conditions have led to interest in observational nonexperimental and quasi-experimental research. These include calls by the National Institutes of Health (PA-05-90) and articles by Black 39 and others 40 in the British Medical Journal. Sequential cohort designs have been helpful to study interventions in settings in which the clinical environment itself is changed by the intervention or other circumstances do not permit randomized clinical trial (RCT). 41 Even where systematic multisite trials may be feasible, a single-site observational study can be helpful before proceeding to more costly designs. 40 
Study Hypotheses
Documentation of patient-reported symptoms, management of symptoms, and HRQOL can be improved through use of the Therapy-Related Symptom Checklist (TRSC) in clinic practice. Study hypotheses are as follows: H1: A treatment cohort using the TRSC at clinic visits will show a statistically significant positive increase in HRQOL-LASA compared with a treatment cohort receiving standard of care.
H2: A treatment cohort using the TRSC during clinic visits will show a statistically significant larger number of symptoms documented and managed compared with a treatment cohort receiving standard of care.
These hypotheses are tested using a sequential cohort design and generalized estimating equations (GEEs).
n Methods
Study Design
This is a quasi-experimental sequential cohort design with cyclical turnover. 41Y44 This design is adequate to assess pre-post changes between control and intervention groups, if there are minimal confounding historical changes, adequate statistical controls, and no changes in personnel or other treatment resources. In this study, G1 and G2 were treated within relatively narrow time frames mitigating time-related confounding. Changes in the primary outcome (HRQOL) were adjusted using patient baseline measures and covariates discussed in the literature. 45 Total number of staff full-time equivalents remained constant throughout the study periods. The practice model also remained unchanged throughout the study periods. The study was approved by the study site's institutional review board.
Participants, Sample, and Setting
Randomization of patient assignment into treatment cohorts was impossible in this study, because 1 outpatient clinic served the site and the intervention would itself alter the delivery of care within the clinic. Use of the TRSC by patients and clinicians would lead to changes in interactions between them and among clinicians. Data, therefore, were collected from 2 cohorts of patients sequentially: one cohort before use of the TRSC (G1) at the clinic and another during TRSC use (G2). Study patients were accrued as they were usually scheduled for treatment at the clinic during each observation period. Eligible patients were invited to participate in the study and an institutional review boardYapproved informed consent was obtained. Inclusion criteria required that study patients had at least 1 day of treatment (radiation, chemotherapy, or both), were not already participating in an ongoing clinical trial, had no diagnosed psychopathology, were 18 years or older, spoke/read English because study forms were not available in other languages, and had an Eastern Cooperative Oncology Group score of 3 or less or Karnofsky score of 60 or greater.
The 2 study cohorts were accrued and followed to the end of each study period: first G1 patients (March 6, 2007, through November 23, 2007) and later G2 patients (May 7, 2008, through March 3, 2009 ). Repeated measures were obtained from 55 patients in G1 and 58 patients in G2 up to and including a predesignated last date of data accrual for each cohort. As a result of the accrual process, the number of patient visits or observations ranged from 1 to 11. Two patients with only a single visit (1 each in G1 and G2) are excluded from analysis and discussion in this article. There was no overlap between patients in groups 1 and 2.
Sample Size
Equations in Twisk 45 were used to estimate power and sample size for the primary study outcome, the HRQOL-LASA total score. An effect size = 0.30, ! = .05, 5 repeated measures per subject, and a desired power = 0.80 led to 55 subjects needing to be obtained from each of the 2 study cohorts (groups) or 110 subjects in total. To allow for withdrawals, losses to follow-up, and incomplete data collection, 64 subjects were actually accrued into each study group.
Demographics of the 113 subjects used in this article appear in Table 1 . Of the 128 subjects on whom data were collected, 2 were excluded for having only 1 visit, and 13 were not able to be staged for their cancer. Stage was considered a critical covariate in the 2 GEEs. Exclusion of these subjects left 113 for the analysis in this article with 696 observations. The mean number of observations per patient was 5.2.
Setting
The study oncology clinic is located in a small city in the US upper Midwest, with population of 107 120 (2005), of which 96%+ is white. The county has 7 major manufacturing companies, 1 state university, 1 private university, 1 technical college, 2 integrated healthcare delivery systems, and other employers in smaller manufacturing companies. The median income of residents was $26 030 (75% of the state's median income). The other 10 counties in the tristate catchment area are similarly situated in terms of mix of economic activities with median incomes below medians in Wisconsin, Minnesota, and Iowa.
The clinic is part of 1 integrated delivery system with 3 hospitals (total of 430+ beds) serving residents in the states mentioned. Cancer services include inpatient and outpatient care at a state-of-the-art Center for Advanced Medicine and Surgery, which opened in 2004 in the city. The physicians in the Division of Hematology/Oncology and Division of Radiation Oncology are all specialists in cancer care. Medical school, residency, and fellowship experiences are from top schools in the United States; all are board certified in their respective specialties, including internal medicine, medical oncology, hematology, and radiation oncology. The nursing staff consists of highly qualified nurses, the majority of whom are oncology certified. Oncology patients also have access to a full set of support services at the clinic.
Standard of Care
Treatment options in the study clinic include chemotherapy and radiation therapy. A wide array of support services is available including assessment and referral for specialized individual and family counseling, support groups, education and resource materials, referral to complementary therapies by patient request, nutritional counseling, social work services, and financial assistance. Documentation of symptoms and their management is done by physicians and nurses using the standard clinic interview and medical record. Health-related quality of life is not documented except when a patient is enrolled in an RCT that requires this. Randomized clinical trials have been exclusively drug trials.
Upon admission for treatment and outpatient follow-up, patients have the option of meeting with a personal cancer guide, an experienced registered nurse. The RN ''Cancer Guide'' helps the patient and a family member if present develop an individualized plan of care that encompasses psychosocial, emotional, and spiritual needs. Nationally recommended research-based clinical protocols are used for all cancer treatments.
Intervention
The first study cohort received standard care at the clinic. Patients were entered into the study during the first 4 months and followed up for a subsequent 4 months. Data were collected from these patients using the HRQOL-LASA, a short demographic data form, a symptom management record and Karnofsky scale, and a medical record review by an experienced RN. 46 Patients who received RT daily completed instruments once weekly on the same day each week. Patients receiving chemotherapy completed the instruments on the day of provider evaluation prior to receiving chemotherapy on day 1 of each cycle. The number of radiation treatments and chemotherapy cycles varied, depending on the treatment protocol. The study coordinator monitored and logged in subjects' schedules.
The second study cohort received the standard of care, and the same instruments were used. In addition, the 25-symptom TRSC was completed by patients prior to clinical consultation. 4Y6 The checklist was answered on a scale of 0 (none or no symptom) to 4 (very severe). The completed TRSC was provided to the clinicians for use or reference during the patient appointment.
Prior to the beginning of the study, clinic staff were trained in the use of the study instruments and the importance of complete and consistent follow-up to accrue at least 5 complete sets of instruments from each patient. Before the beginning of accrual of the second or intervention study cohort, clinic staff was introduced to the TRSC and advised that on the patients' completion of the form the provider was to be given a copy. No training was provided as to how this form was to be used with patients. Patients were to be accrued as usual by the clinic.
Study Variables and Instruments
The study variables are shown in Chart 1, and instruments or measures used, including the symptom documentation for the non-TRSC group, in Chart 2. During G1, a trained oncology nurse abstracted the symptoms managed and documented after each clinic visit; another nurse checked accuracy. These data
Chart 1 & Study Variables
1. Total HRQOL-LASA score. This measure is briefly described in Chart 2. 2. Number of symptoms documented and managed (total number of symptoms). For G1, the number of symptoms managed and documented was a count of the number of symptoms obtained from medical record review by a trained oncology nurse abstractor (see Chart 2) . For G2, the number of symptoms documented and managed was a count of the symptoms reported on the completed TRSC. For both G1 and G2, the nurse examined medical records to validate symptom management. One study hypothesis was that the number of symptoms documented and managed would be greater in G2 than in the standard-of-care group (G1). The TRSC is briefly described in Chart 2. The main study variable is 3. TRSC group placement (intervention group) is an indicator variable (G: 1 = G2, 0 = G1). The primary study hypothesis is that the parameter of this variable will be 90 with P e .05 with respect to HRQOL. The study covariates are 4. Baseline QOL is the HRQOL-LASA score measured at baseline (first visit after entry into the study) 5. Education level (education) is the level of education attained by the patient ranging from 1 = less than high school to 5 = graduate school. 6. Age is age in years of the patient at entry to the study. 7. Male is the gender of the patient, M = 1, F = 0. 8. Significant other is the presence of a significant other in the household, yes = 1, no = 0. 9. Stage is the documented stage of the cancer upon entry to the study. Stage is rank ordered from I to IV.
Radiotherapy is an indicator variable (1 = yes; 0 = no)
if radiotherapy was documented after entry into the study.
Chemotherapy is an indicator variable (1 = yes; 0 = no)
if chemotherapy was documented after entry into the study. By implication scores of 1 on both radiotherapy and chemotherapy indicate combined therapy. 12.Days from baseline entry into the study (time) is a cumulative count of the number of days from entry into the study (time) to the day at which each set of observations is collected from each study patient. 13. Interaction effects of days from baseline on group placement is time * group placement, which is used to capture the combined effects of time and group placement. The multiplication of independent variables in a regression equation is commonly used to capture the effects of 2 or more variables together on a dependent variable, thus the term interaction effects. 47 Abbreviations: F, female; G1, group 1; G2, group 2; HRQOL-LASA, Health-Related Quality of Life Linear Analogue Self-assessment; M, male; QOL, quality of life; TRSC, Therapy-Related Symptom Checklist.
Chart 2 & Study Instruments
1. The TRSC 4Y8,27 is a patient self-report instrument that can serve as both a guide (checklist) helpful to clinicians before and during patient consults and a subjective measure of therapy-related symptom severity of concern to patients. Each of the 25 symptoms on the TRSC is rated by patients using a 5-point scale, 0 (not present) to 4 (very severe). Thus, the total or summated TRSC score indicates both symptom occurrence and severity. Physical and psychological symptoms are included on the checklist. Additional symptoms can be added to the checklist by patients using 5 blank spaces and rated for symptom severity. Fewer than 2% of patients seen in clinics or in studies have added symptoms to the checklist. 4Y8,27 Studies have reported good measurement properties of the TRSC. The TRSC is simple to administer in busy clinics and has been a clinically useful self-report checklist. The summated TRSC score correlates well with health-related quality-of-life measures including the Functional Assessment of Cancer TherapyYGeneral. 33 The TRSC captures patient symptom concerns of both radiotherapy and chemotherapy patients. 1 were then entered as string variables into a computer database. On a regular basis, these data were checked by the data analyst, the principal investigators and consultants to the study, and members of the research team. All instruments used have good psychometric properties, including the TRSC. 4Y9,27 The major outcome measure is the HRQOL-LASA. 37, 38 The TRSC is shown in the Appendix.
Data Analysis
A statistician not involved in the collection and review of data conducted the statistical analysis. Stata version 11.0 was used for all analyses. 49 The Stata routines are adjusted for censoring, and semirobust SEs were obtained. Only subjects with 2 or more clinic visits and documented stage were retained in the analysis.
The first study hypothesis was examined using the HRQOL measures in a panel analysis: specifically, a population averaged GEE with a Gaussian distribution, identity link, and exchangeable correlation matrix. Health-related quality of life was measured during visits 1 to 11. The first observation of HRQOL was used as a baseline covariate in the GEE. Because of the use of an HRQOL baseline, the final analysis was done with 583 observations of 113 subjects. The key study variable was group placement. Covariates in addition to the baseline HRQOL were education level attained by the respondent, age in years, gender, whether a significant other is in household, stage, radiotherapy, chemotherapy, and by implication combined treatment if radiotherapy = 1 and chemotherapy = 1. Time measured as days postbaseline was also included as a covariate. This equation was tested for interaction effects among the independent variables, and none were found.
The second study hypothesis was examined using a similar GEE; however, the dependent variable was total number of reported symptoms at each clinic visit (1Y11 [mean, 5.2 visits per patient]). This analysis was done with 113 subjects and 696 observations. Covariates were those mentioned previously plus an interaction effect measured as days from baseline multiplied by group placement: this variable is used to capture the combined effects of time and group placement. The multiplication of independent variables in a regression equation is commonly used to capture the effects of 2 or more variables acting together on a dependent variable, thus the term interaction effects. 47 n Results
Participants: Sociodemographic and Clinical Characteristics
As Table 1 shows, the only statistically significant baseline difference between subjects in G1 and G2 was age. At group means, G1 subjects on average were 4.09 years older than those in G2 (P = .03); however, there is no statistically significant difference in median age. The GEE equations used in this study are age adjusted. Comparisons also were done (not shown here) of demographics between the 696 observations with results similar to those in Table 1 .
Outcome Data, Main Results

Primary Outcomes
As noted previously, the primary study hypothesis was the effect of TRSC group (G2) assignment on patients. The results of the GEE used to measure this effect are shown in Table 2 .
As anticipated, the largest single effect on HRQOL was the baseline HRQOL covariate. Placement in the TRSC group raised quality of life on average by 3.31 points. A 3-point change on this measure is considered clinically significant. Male gender was associated on average with a lowered quality of life of 3.24 points. None of the other covariates were statistically significant.
Secondary Outcomes
An outcome of secondary interest was the effect of TRSC group placement on the number of symptoms identified and managed. Generalized estimating equation results are shown in Table 3 .
Placement in the TRSC group (G2) had a strong effect on the number of symptoms documented and managed (P G .001). The number of symptoms documented and managed was on average 3.76 more than in G1. Stage also had an effect on the number of symptoms reported. The number of symptoms documented and managed increased by 0.76 for each stage greater than stage I, the reference stage (P G .03). The interaction between TRSC group placement and the number of days postbaseline was strong, with the number of symptoms declining on average about 0.015 each day postbaseline in G2. In summary, a greater number of symptoms was identified and managed in G2 than in the standard-of-care cohort, and in G2, the number of symptoms declined by about 1.5 every 100 days postbaseline more than in the standard-of-care cohort. 
Other Outcomes of Clinical Interest
As in earlier studies, 4Y8,27,33,48,50 the TRSC total scores, the HRQOL-LASA, and Karnofsky all correlated significantly (P G .001) and in the expected directions. The Pearson correlations between the Karnofsky, HRQOL, and total TRSC score in the current study were 0.42 and j0.47, respectively, and between the HRQOL and TRSC, j0.47. The correlation between the total TRSC score and the total number of symptoms reported was 0.74, which suggests that the number of symptoms reported by patients on the TRSC may capture both frequency and intensity. Additionally, it should be noted that fewer than 2% of patients seen have added symptoms to the checklist, although 5 blank spaces are available to do so. 4Y8,27,33,48,50Y52 Physical and psychological symptoms are included in the TRSC. The 25 symptoms on the TRSC are as follows: taste change, loss of appetite, nausea, vomiting, weight loss, sore mouth, cough, sore throat, difficulty swallowing, jaw pain, shortness of breath, numbness of fingers/toes, feeling sluggish, depression, difficulty concentrating, fever, bruising, bleeding, hair loss, skin changes, soreness in vein where chemotherapy was given, difficulty sleeping, pain, decreased interest in sexual activity, constipation. Consistent with the literature, 4Y9,27,33,48,50Y52 among the most frequently occurring and severe symptoms marked on the TRSC and reported as being managed were loss of appetite and nausea. n Discussion, Implications, and Conclusions
The findings of this study are important. Health-Related Quality of Life LASA increased by both a statistically significant and clinically significant amount when the TRSC was used in the clinic setting. Additionally, although the study findings show that the number of symptoms identified and managed increased when the TRSC was implemented, symptom scores decreased significantly over time in the TRSC cohort. Although this study did not directly investigate the degree to which HRQOL improved because of better identification and management of patient symptoms, it is likely that this accounts for a considerable proportion of the better outcomes in the TRSC group.
The HRQOL and symptom findings are consistent with earlier studies by 2 of the authors that have shown that symptoms of concern to patients are greatly underdocumented in medical records and in the standard clinic interview. The development of the TRSC, which began in 1984, 1,3Y9,27 preceded recent efforts by clinicians and researchers that urge use of checklists and other tools to obtain consistent clinically relevant information about patient perceptions, concerns, and preferences. Moreover, patients who participated in symptom monitoring using the TRSC are satisfied and interact with providers more regarding symptom management. 33, 51 As noted, the TRSC includes physical and psychological symptoms. The TRSC correlates with HRQOL measures including the Functional Assessment of Cancer TherapyYGeneral. 33 Use of the TRSC as in this study can be extended to address a number of recent interests including more systematic study of patientreported outcomes. 53 This study has some limitations. An RCT might follow this study, but an RCT would require a large number of participating clinics and patients and could be rather costly. A significant limitation is the lack of minority representation due to population demographics at the study site. This study, however, at the least suggests that a working-class, lower-middleincome population can benefit from TRSC use. This is a large population that has been hard pressed by economic change in the United States and in the community used in this study. The TRSC might produce similar results in different populations, but this might require adjustments in how it is used and clinical services are delivered. Two of the authors of this study and others have research completed and underway that has included African Americans, Hispanics in the United States, and patients in Puerto Rico, 48, 50, 52 as well as completed studies in Asia. 7, 8, 27 Implications Unlike many tools purported to be usable in clinics, the TRSC was developed to address a specific clinical need: the underdocumentation of a wide array of symptoms of concern to patients receiving treatment for cancer. Later studies have found that subscales of clinical interest are measured on this instrument and that the instrument has desirable psychometric properties that were not anticipated when this checklist was developed. 1,4Y9,27,33 The TRSC is easy to answer and can be completed quickly in clinic settings. The TRSC was developed from the bottom-up to meet patient and clinician needs, 9 and the results of this study and others indicate that this tool works well in clinic settings, patient-centered care, and evidence-based practice. 48,50Y52,54,55 Recent research has suggested that the use of checklists can have a powerful influence on both the quality and safety of healthcare services and patient outcomes. The findings of this study are very consistent with such a ''checklist manifesto'' 56 and even suggest that, during cancer treatment, improved patient outcomes arise from better symptom management and symptom reduction as a consequence of checklist use by clinicians. A newly calibrated TRSC checklist for children (TRSC-C) is published in 2012 in Cancer Nursing. 57 The TRSC-C uses childfriendly terms for each symptom.
In conclusion, use of the patient-friendly TRSC by patients and clinicians in a cancer clinic improves symptom documentation and management and patient HRQOL. Systematic use of checklists can have significant positive influences on the quality and safety of patient treatments and outcomes, especially if these tools can be easily completed in clinics without burdening patients and clinicians. 1, 33, 51, 52, 58 
